Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsule

References

• Anderson BJ, Holford NH. (2008). Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–32.
   PubMed Web of Science ®Google Scholar
• Andreu F, Colom H, Grinyo JM, et al. (2015). Development of a population PK model of tacrolimus for adaptive dosage control in stable kidney transplant patients. Ther Drug Monit 37:246–55.
   PubMed Web of Science ®Google Scholar
• Benkali K, Rostaing L, Premaud A, et al. (2010). Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation. Clin Pharmacokinet 49:683–92.
   PubMed Web of Science ®Google Scholar
• Bergmann TK, Hennig S, Barraclough KA, et al. (2014). Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit 36:62–70.
   PubMed Web of Science ®Google Scholar
• Bonate PL. (2001). A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 40:15–22.
   PubMed Web of Science ®Google Scholar
• Butani L, Ramsamooj R. (2009). Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 24:1517–23.
   PubMed Web of Science ®Google Scholar
• Certikova-Chabova V, Tesar V. (2013). Recent insights into the pathogenesis of nephrotic syndrome. Minerva Med 104:333–47.
   PubMed Web of Science ®Google Scholar
• Chandrasekhara PK, Jayachandran NV, Thomas J, et al. (2009). Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol 28:489–90.
   PubMed Web of Science ®Google Scholar
• Choudhry S, Bagga A, Hari P, et al. (2009). Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 53:760–9.
   PubMed Web of Science ®Google Scholar
• Eddy AA, Symons JM. (2003). Nephrotic syndrome in childhood. Lancet 362:629–39.
   PubMed Web of Science ®Google Scholar
• Fay JW, Nash RA, Wingard JR, et al. (1995). FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. Transplant Proc 27:1374.
   PubMed Web of Science ®Google Scholar
• Fay JW, Wingard JR, Antin JH, et al. (1996). FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 87:3514–9.
   PubMed Web of Science ®Google Scholar
• Fukudo M, Yano I, Masuda S, et al. (2006). Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80:331–45.
   PubMed Web of Science ®Google Scholar
• Garcia Sanchez MJ, Manzanares C, Santos-Buelga D, et al. (2001). Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. Clin Pharmacokinet 40:63–71.
   PubMed Web of Science ®Google Scholar
• Gulati A, Sinha A, Gupta A, et al. (2012). Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome. Kidney Int 82:1130–5.
   PubMed Web of Science ®Google Scholar
• Gulati S, Prasad N, Sharma RK, et al. (2007). Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 23:910–3.
   PubMed Web of Science ®Google Scholar
• Guy-Viterbo V, Scohy A, Verbeeck RK, et al. (2013). Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation. Eur J Clin Pharmacol 69:1533–42.
   PubMed Web of Science ®Google Scholar
• Han N, Ha S, Yun HY, et al. (2014). Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol 114:400–6.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhou H, Cai J, et al. (2019). Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach. Pharmacogenomics 20:21–35.
   PubMed Web of Science ®Google Scholar
• Hao GX, Huang X, Zhang DF, et al. (2018). Population pharmacokinetics of tacrolimus in children with nephrotic syndrome. Br J Clin Pharmacol 84:1748–56.
   PubMed Web of Science ®Google Scholar
• Haufroid V, Mourad M, Van Kerckhove V, et al. (2004). The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14:147–54.
   PubMedGoogle Scholar
• Hesselink DA, van Schaik RH, van der Heiden IP, et al. (2003). Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 74:245–54.
   PubMed Web of Science ®Google Scholar
• Jalil MH, Hawwa AF, McKiernan PJ, et al. (2014). Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients. Br J Clin Pharmacol 77:130–40.
   PubMed Web of Science ®Google Scholar
• Jusko WJ, Piekoszewski W, Klintmalm GB, et al. (1995). Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57:281–90.
   PubMed Web of Science ®Google Scholar
• Kassir N, Labbe L, Delaloye JR, et al. (2014). Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients. Br J Clin Pharmacol 77:1051–63.
   PubMed Web of Science ®Google Scholar
• Koskimies O, Vilska J, Rapola J, Hallman N. (1982). Long-term outcome of primary nephrotic syndrome. Arch Dis Child 57:544–8.
   PubMed Web of Science ®Google Scholar
• Lindbom L, Pihlgren P, Jonsson EN. (2005). PsN-Toolkit – a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 79:241–57.
   PubMed Web of Science ®Google Scholar
• Loeffler K, Gowrishankar M, Yiu V. (2004). Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 19:281–7.
   PubMed Web of Science ®Google Scholar
• Lombel RM, Gipson DS, Hodson EM. (2013). Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 28:415–26.
   PubMed Web of Science ®Google Scholar
• McKinney PA, Feltbower RG, Brocklebank JT, Fitzpatrick MM. (2001). Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatr Nephrol 16:1040–4.
   PubMed Web of Science ®Google Scholar
• Monchaud C, de Winter BC, Knoop C, et al. (2012). Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet 51:175–86.
   PubMed Web of Science ®Google Scholar
• Mould DR, Upton RN. (2012). Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1:e6.
   PubMedGoogle Scholar
• Nash RA, Antin JH, Karanes C, et al. (2000). Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96:2062–8.
   PubMed Web of Science ®Google Scholar
• Nash RA, Etzioni R, Storb R, et al. (1995). Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. Blood 85:3746–53.
   PubMed Web of Science ®Google Scholar
• Nash RA, Pineiro LA, Storb R, et al. (1996). FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. Blood 88:3634–41.
   PubMed Web of Science ®Google Scholar
• Niu WJ, Sun T, Liu L, et al. (2019). Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV. Basic Clin Pharmacol Toxicol 124:456–65.
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Ippoliti C, Khouri I, et al. (1996). Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 88:4383–9.
   PubMed Web of Science ®Google Scholar
• Qin XL, Bi HC, Wang CX, et al. (2010a). Study of the effect of Wuzhi tablet (Schisandra sphenanthera extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. Biomed Chromatogr 24:399–405.
   PubMed Web of Science ®Google Scholar
• Qin XL, Bi HC, Wang XD, et al. (2010b). Mechanistic understanding of the different effects of Wuzhi Tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). Int J Pharm 389:114–21.
   PubMed Web of Science ®Google Scholar
• Roberti I, Vyas S. (2010). Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 25:1117–24.
   PubMed Web of Science ®Google Scholar
• Sam WJ, Aw M, Quak SH, et al. (2001). Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 50:531–41.
   Web of Science ®Google Scholar
• Shimizu M, Ueno K, Ishikawa S, et al. (2014). Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus. Rheumatology 53:2120–2.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Tsugawa K, Suzuki K, et al. (2007). Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. Eur J Pediatr 166:1053–5.
   PubMed Web of Science ®Google Scholar
• Tarshish P, Tobin JN, Bernstein J, Edelmann CM. Jr. (1997). Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–76.
   PubMed Web of Science ®Google Scholar
• Uberti JP, Silver SM, Adams PT, et al. (1997). Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies. Bone Marrow Transplant 19:1233–8.
   PubMed Web of Science ®Google Scholar
• Vadcharavivad S, Praisuwan S, Techawathanawanna N, et al. (2016). Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. J Clin Pharm Ther 41:310–28.
   PubMed Web of Science ®Google Scholar
• Wallin JE, Bergstrand M, Wilczek HE, et al. (2011). Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance. Ther Drug Monit 33:663–72.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen X, Li Z. (2019a). Treatment of patients with systemic-onset juvenile idiopathic arthritis with tacrolimus. Exp Ther Med 17:2305–9.
   PubMed Web of Science ®Google Scholar
• Wang D, Chen X, Xu H, Li Z. (2019b). Population pharmacokinetics and dosing regimen optimisation of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. Xenobiotica 1–29. doi: 10.1080/00498254.2019.1601791. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Wang D, Lu J, Li Q, Li Z. (2019c). Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. Exp Ther Med 17:4023–31.
   PubMed Web of Science ®Google Scholar
• Wang DD, Chen X, Fu M, et al. (2019d). Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients. Xenobiotica 1–9. doi: 10.1080/00498254.2019.1631505. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Wang DD, Chen X, Li ZP. (2018a). Efficacy and safety of tacrolimus in treating pediatric refractory nephrotic syndrome: a meta-analysis. Int J Clin Exp Med 11:6436–44.
   Web of Science ®Google Scholar
• Wang DD, Lu JM, Li Q, Li ZP. (2018b). Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther 43:476–83.
   PubMed Web of Science ®Google Scholar
• Wei H, Tao X, Di P, et al. (2013). Effects of traditional chinese medicine Wuzhi capsule on pharmacokinetics of tacrolimus in rats. Drug Metab Dispos 41:1398–403.
   PubMed Web of Science ®Google Scholar
• Xin HW, Li Q, Wu XC, et al. (2011). Effects of Schisandra sphenanthera extract on the blood concentration of tacrolimus in renal transplant recipients. Eur J Clin Pharmacol 67:1309–11.
   PubMed Web of Science ®Google Scholar
• Xin HW, Wu XC, Li Q, et al. (2007). Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 64:469–75.
   PubMed Web of Science ®Google Scholar
• Yang EM, Lee ST, Choi HJ, et al. (2016). Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula. World J Pediatr 12:60–5.
   PubMed Web of Science ®Google Scholar
• Yang JW, Liao SS, Zhu LQ, et al. (2015). Population pharmacokinetic analysis of tacrolimus early after Chinese pediatric liver transplantation. Int J Clin Pharmacol Ther 53:75–83.
   PubMed Web of Science ®Google Scholar
• Yasuhara M, Hashida T, Toraguchi M, et al. (1995). Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27:1108–10.
   PubMed Web of Science ®Google Scholar
• Zhao W, Elie V, Roussey G, et al. (2009). Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther 86:609–18.
   PubMed Web of Science ®Google Scholar
• Zuo XC, Ng CM, Barrett JS, et al. (2013). Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis. Pharmacogenet Genomics 23:251–61.
   PubMed Web of Science ®Google Scholar